These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 29314183)

  • 1. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.
    Abdallah H; Hsu JC; Lu P; Fettner S; Zhang X; Douglass W; Bao M; Rowell L; Burmester GR; Kivitz A
    J Clin Pharmacol; 2017 Apr; 57(4):459-468. PubMed ID: 27599663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
    Frey N; Grange S; Woodworth T
    J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components.
    Bastida C; Soy D; Ruiz-Esquide V; Sanmartí R; Huitema ADR
    Br J Clin Pharmacol; 2019 Aug; 85(8):1710-1718. PubMed ID: 30958574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.
    Moes DJAR; van Westerloo DJ; Arend SM; Swen JJ; de Vries A; Guchelaar HJ; Joosten SA; de Boer MGJ; van Gelder T; van Paassen J
    Clin Pharmacokinet; 2022 Feb; 61(2):231-247. PubMed ID: 34633645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.
    Ternant D; Ducourau E; Fuzibet P; Vignault C; Watier H; Lequerré T; Le Loët X; Vittecoq O; Goupille P; Mulleman D; Paintaud G
    Br J Clin Pharmacol; 2015 Feb; 79(2):286-97. PubMed ID: 25223394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations.
    Bastida C; Huitema ADR; l'Ami MJ; Ruiz-Esquide V; Wolbink GJ; Sanmartí R; Soy D
    Eur J Clin Pharmacol; 2020 Oct; 76(10):1417-1425. PubMed ID: 32514745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
    Paccaly AJ; Kovalenko P; Parrino J; Boyapati A; Xu C; van Hoogstraten H; Ishii T; Davis JD; DiCioccio AT
    J Clin Pharmacol; 2021 Jan; 61(1):90-104. PubMed ID: 32726514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Population Pharmacokinetic Model of Tocilizumab in Kidney Transplant Patients Treated for Chronic Active Antibody-Mediated Rejection: Comparison of Plasma Exposure Between Intravenous and Subcutaneous Administration Schemes.
    Arrivé C; Bazzoli C; Jouve T; Noble J; Rostaing L; Stanke-Labesque F; Djerada Z
    BioDrugs; 2024 Sep; 38(5):703-716. PubMed ID: 39147956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis.
    Xu C; Su Y; Paccaly A; Kanamaluru V
    Clin Pharmacokinet; 2019 Nov; 58(11):1455-1467. PubMed ID: 31055792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.
    Morcos PN; Zhang X; McIntyre C; Bittner B; Rowell L; Hussain Z
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):537-48. PubMed ID: 23547849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
    Levi M; Grange S; Frey N
    J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
    Hooijberg F; Layegh Z; Leeuw M; Boekel L; van den Berg SPH; Ruwaard J; Bastida C; Huitema ADR; Pel S; Elkayam O; de Vries A; Nurmohamed M; Rispens T; Dorlo TPC; Wolbink G
    Ther Drug Monit; 2024 Jun; 46(3):410-414. PubMed ID: 38287880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
    Farrell C; Schweizer C; Wustner J; Weil S; Namiki M; Nakano T; Nakai K; Phillips MD
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):727-34. PubMed ID: 22955257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.
    Gibiansky L; Frey N
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):5-16. PubMed ID: 22101760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
    Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.